Telomir Pharmaceuticals, Inc. Common Stock
TELO
Rank in Stocks
#22675
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical... Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Share Price
$0.69
Last synced: 2026-11-09
Market Cap
$50.84M
Change (1 day)
-2.83%
Change (1 year)
-51.41%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Telomir Pharmaceuticals, Inc. Common Stock (TELO)
Category
Healthcare
EPS for Telomir Pharmaceuticals, Inc. Common Stock (TELO)
EPS as of September 2026 TTM: $-1.49
According to Telomir Pharmaceuticals, Inc. Common Stock's latest financial reports, its current EPS (TTM) is $-1.49. At the end of 2025 the company had an EPS of $-0.33, an increase over its 2024 EPS of $-0.56.
EPS history for Telomir Pharmaceuticals, Inc. Common Stock from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.49 | 351.52% |
| 2025 | $-0.33 | -41.07% |
| 2024 | $-0.56 | 27.27% |
| 2023 | $-0.44 | 1,427.78% |
| 2022 | $-0.03 | 512.77% |
| 2021 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,151.01% |
US
|
|
| $-7.07 | 374.50% |
US
|
|
| $-5.29 | 255.03% |
AU
|
|
| $12.88 | -964.44% |
BE
|
|
| $21.56 | -1,546.98% |
NL
|
Questions about Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS)
What is Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS)?
Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS) over the last twelve months is $-1.49, as of Sep 2026.
What was Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS) in 2025?
In 2025, Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS) was $-0.33, compared with $-0.56 in 2024.
How has Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS) changed since 2021?
From 2021 to 2025, Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS) was highest in 2021 (0.00) and lowest in 2024 ($-0.56).
How does Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS) compare with similar companies?
Telomir Pharmaceuticals, Inc. Common Stock's earnings per share (EPS) ($-1.49) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.